Currus Biologics Pty

HS-19-647 is a Phase 3 clinical trial evaluating octreotide subcutaneous depot (CAM2029), a somatostatin receptor agonist developed by Camurus Pty Ltd for the treatment of acromegaly. Octreotide is an established small-molecule therapeutic agent already approved in multiple jurisdictions including Australia, the European Union, and China, where it is marketed under various brand names including OCTREOTIDE (SUN). The current trial is an open-label, single-arm, multi-center study designed to assess the long-term safety profile of the subcutaneous depot formulation in acromegaly patients.

Camurus' strategy centers on advancing a depot formulation of an existing, well-characterized somatostatin receptor agonist, potentially offering improved dosing convenience and patient compliance compared to standard octreotide administration. Octreotide has demonstrated regulatory approval in Australia since 1998 and in the European Union, with multiple manufacturers holding marketing authorizations. The current Phase 3 program represents a late-stage development effort focused on establishing the safety and tolerability profile necessary for regulatory submission and market authorization of the depot formulation.

The trial is registered under NCT 2024-510667-33-00 and remains active. No projected peak sales, consensus positioning, or specific expected milestone dates have been disclosed. The competitive landscape for acromegaly includes multiple approved therapies targeting different mechanisms, including somatostatin receptor agonists (SIGNIFOR, PALSONIFY), growth hormone receptor antagonists (SOMAVERT), and insulin-like growth factor I receptor agonists (INCRELEX).

Acromegaly is a chronic endocrine disorder characterized by excessive growth hormone secretion, resulting in significant morbidity including cardiovascular complications, metabolic dysfunction, and reduced quality of life. Current treatment options require frequent dosing schedules or invasive administration routes, creating an unmet need for improved formulations that enhance patient convenience and compliance while maintaining therapeutic efficacy.

The octreotide depot formulation addresses this clinical need by potentially extending the dosing interval through subcutaneous depot technology, reducing treatment burden for patients requiring long-term somatostatin receptor agonist therapy. Octreotide remains a cornerstone therapy for acromegaly management, with established safety and efficacy data spanning decades of clinical use. A depot formulation could enhance market penetration by improving patient adherence and reducing healthcare resource utilization associated with frequent dosing.

Commercially, the acromegaly treatment market encompasses multiple approved therapies with distinct mechanisms of action. The competitive environment includes established somatostatin receptor agonists (SIGNIFOR, PALSONIFY), growth hormone receptor antagonists (SOMAVERT), and IGF-I receptor agonists (INCRELEX). A long-acting octreotide depot could capture market share by offering a familiar, well-tolerated mechanism with improved convenience. The patient population, while relatively small, represents a chronic disease requiring lifelong management, supporting sustained commercial opportunity. Regulatory approval of the depot formulation would expand Camurus' portfolio and potentially establish a new standard of care for octreotide-based acromegaly management.

Drug Class: Somatostatin receptor agonist; Systemic hormonal preparation (ATC H01).

Mechanism of Action: Octreotide is a synthetic somatostatin analog that binds to and activates somatostatin receptors, suppressing growth hormone and insulin-like growth factor I secretion in acromegaly patients.

Modality: Small molecule.

Route of Administration: Subcutaneous depot injection (CAM2029 formulation).

Molecular Target: Somatostatin receptors (specific receptor subtypes not disclosed in available facts).

Related Therapies: Other somatostatin receptor agonists approved for acromegaly include SIGNIFOR (pasireotide, somatostatin receptor 1 agonist) and PALSONIFY (capromorelin, somatostatin receptor 2 agonist). Alternative mechanisms include growth hormone receptor antagonists (SOMAVERT, pegvisomant) and insulin-like growth factor I receptor agonists (INCRELEX, mecasermin).

First Approval: Octreotide was first approved in Australia on 1 February 1998. European Union approvals were granted on 2 December 2022 (Camurus AB) and 2 December 2025 (Amryt Pharmaceuticals DAC). The specific formulation CAM2029 (subcutaneous depot) is currently in Phase 3 development.

Patent Status: Not yet disclosed in available facts.

Australia (TGA): Octreotide is approved and listed on the Australian Register of Therapeutic Goods (ARTG) with multiple PBS codes (10533J, 10543X, 10549F, 10550G, 10558Q, 10566D, 11501H, 11512X, 11537F, 11893Y) under multiple sponsors: Generic Health Pty Ltd (first listed 1 February 1998), Novartis Pharmaceuticals Australia Pty Limited (first listed 1 July 2010), and Sun Pharma ANZ Pty Ltd (first listed 1 December 2012).

European Union (EMA): Octreotide formulations hold European Union marketing authorizations: Camurus AB (EMEA/H/C/006322, authorized 2 December 2022) and Amryt Pharmaceuticals DAC (EMEA/H/C/005826, authorized 2 December 2025).

China (NMPA): Octreotide is in clinical trials in China; NCT02409849 is registered for clinical trial activity.

United States (FDA): Regulatory status not yet disclosed in available facts.

Current Program Status: HS-19-647 (CAM2029, octreotide subcutaneous depot) is in Phase 3 development. The trial is registered as NCT 2024-510667-33-00 and remains active. Expected regulatory submission timeline and approval dates are not yet disclosed. No label expansion or additional regulatory milestones have been disclosed.

Strategic Positioning: Camurus' development of a subcutaneous depot formulation of octreotide represents a formulation optimization strategy applied to an established, well-characterized active ingredient. This approach leverages decades of octreotide safety and efficacy data while addressing the clinical need for improved dosing convenience in chronic acromegaly management. The Phase 3 focus on long-term safety reflects regulatory expectations for chronic endocrine therapies.

Competitive Implications: The octreotide depot formulation competes within the somatostatin receptor agonist segment against SIGNIFOR and PALSONIFY, and more broadly against alternative mechanisms (growth hormone receptor antagonists, IGF-I receptor agonists). Success depends on demonstrating superior long-term safety and tolerability profiles, improved pharmacokinetic properties enabling extended dosing intervals, and favorable health economic outcomes. The established safety profile of octreotide provides a competitive advantage in regulatory discussions and clinical adoption.

Future Catalysts: Key milestones include completion of the Phase 3 safety trial, regulatory submission to major authorities (FDA, EMA, PMPA), and potential regulatory approvals. Commercial success will depend on regulatory approval timelines, reimbursement decisions, and market penetration relative to existing somatostatin receptor agonists. Post-approval, label expansion studies or comparative efficacy trials may be pursued.

Expected Milestones: Specific expected milestone dates and regulatory submission timelines are not yet disclosed. Trial completion and regulatory submission timing remain to be announced.